Lilly’s Strong Alimta Pivotal Study Obviated Need For Second Trial – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The significant survival benefit seen with Alimta in Lilly’s sole pivotal mesothelioma trial appears to have obviated FDA’s need for efficacy data from a second study.